Download - AWMF
Download - AWMF Download - AWMF
013/065 Leitlinie Rosazea aktueller Stand: 03/2013 71. Ozturkcan S, Ermertcan AT, Sahin MT, Afsar FS. Efficiency of benzoyl peroxideerythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol. 2004; 31: 610-7. 72. Dahl MV, Katz HI, Krueger GG,et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998; 134: 679-83. 73. Fowler J, Jarratt M, Moore A, et al. Brimonidine Phase IISG. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012; 166: 633-41. 74. Tirnaksiz F, Kayis A, Celebi N, et al. Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chem Pharm Bull. 2012; 60: 583-92. 75. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966; 78: 649- 52. 76. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007; 12: 1-5, 9. 77. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54: 258-65. 78. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012; 132: 1435-42. 79. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis 1991; 48: 411-7. 80. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today. 2007; 43: 27-34. 81. McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010; 11: 217-22. 82. Del Rosso JQ, Webster GF, Jackson M, et al Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007; 56: 791-802. 83. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008; 7: 573-6. 84. Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges. 2011; 9: 904-7. 85. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Therap 2005; 27: 1329-42. 86. Lebrun-Vignes B, Kreft-Jais C, Castot A, et al. French Network of Regional Centers of P. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol. 2012; 166: 1333-41. Seite 26 von 29
013/065 Leitlinie Rosazea aktueller Stand: 03/2013 87. Korting HC, Schollmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009; 22: 287-94. 88. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997; 36: 942-6. 89. Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol 2004; 43: 151-4. 90. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976; 1: 1211-2. 91. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102: 443-5. 92. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet. 1971; 2: 1049-52. 93. Nikolowski J, Plewig G. [Rosacea. Oral therapy with 13-cis retinoic acid]. Hautarzt 1980; 31: 660-1. 94. Schmidt JB, Raff M. [13-Cis-retinoic acid: a new form of treatment of rosacea (author's transl)]. Wien Klin Wochensch. 1982; 94: 115-8. 95. Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol 1984; 9: 484-8. 96. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986; 25: 660-3. 97. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998; 134: 884-5. 98. Gollnick H, Blume-Peytavi U, Szabo EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010; 8: 505-15. 99. Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose isotretinoin. Act Dermatol Venereol. 2010; 90: 409-10. 100. Fowler JF, Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007; 6: 641-5. 101. Sanchez J, Somolinos AL, Almodovar PI, et al. A randomized, double-blind, placebocontrolled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005; 53: 791-7. 102. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol 2010; 9: 607-13. 103. Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol 2012; 11: 838-44. 104. Nybaek H, Jemec GB. Photodynamic therapy in the treatment of rosacea. Dermatology. 2005; 211: 135-8. Seite 27 von 29
- Seite 1 und 2: 013/065 Leitlinie Rosazea aktueller
- Seite 3 und 4: 013/065 Leitlinie Rosazea aktueller
- Seite 5 und 6: 013/065 Leitlinie Rosazea aktueller
- Seite 7 und 8: 013/065 Leitlinie Rosazea aktueller
- Seite 9 und 10: 013/065 Leitlinie Rosazea aktueller
- Seite 11 und 12: 013/065 Leitlinie Rosazea aktueller
- Seite 13 und 14: 013/065 Leitlinie Rosazea aktueller
- Seite 15 und 16: 013/065 Leitlinie Rosazea aktueller
- Seite 17 und 18: 013/065 Leitlinie Rosazea aktueller
- Seite 19 und 20: 013/065 Leitlinie Rosazea aktueller
- Seite 21 und 22: 013/065 Leitlinie Rosazea aktueller
- Seite 23 und 24: 013/065 Leitlinie Rosazea aktueller
- Seite 25: 013/065 Leitlinie Rosazea aktueller
- Seite 29: 013/065 Leitlinie Rosazea aktueller
013/065 Leitlinie Rosazea aktueller Stand: 03/2013<br />
87. Korting HC, Schollmann C. Tetracycline actions relevant to rosacea treatment. Skin<br />
Pharmacol Physiol. 2009; 22: 287-94.<br />
88. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the<br />
treatment of rosacea. Int J Dermatol 1997; 36: 942-6.<br />
89. Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int<br />
J Dermatol 2004; 43: 151-4.<br />
90. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976; 1: 1211-2.<br />
91. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline<br />
therapy for rosacea. Br J Dermatol 1980; 102: 443-5.<br />
92. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea.<br />
A controlled trial. Lancet. 1971; 2: 1049-52.<br />
93. Nikolowski J, Plewig G. [Rosacea. Oral therapy with 13-cis retinoic acid]. Hautarzt<br />
1980; 31: 660-1.<br />
94. Schmidt JB, Raff M. [13-Cis-retinoic acid: a new form of treatment of rosacea<br />
(author's transl)]. Wien Klin Wochensch. 1982; 94: 115-8.<br />
95. Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin<br />
Exp Dermatol 1984; 9: 484-8.<br />
96. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol.<br />
1986; 25: 660-3.<br />
97. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in<br />
patients with treatment-resistant rosacea. Arch Dermatol 1998; 134: 884-5.<br />
98. Gollnick H, Blume-Peytavi U, Szabo EL, et al. Systemic isotretinoin in the treatment of<br />
rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol<br />
Ges. 2010; 8: 505-15.<br />
99. Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose<br />
isotretinoin. Act Dermatol Venereol. 2010; 90: 409-10.<br />
100. Fowler JF, Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg<br />
doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel<br />
1% in the treatment of rosacea. J Drugs Dermatol 2007; 6: 641-5.<br />
101. Sanchez J, Somolinos AL, Almodovar PI, et al. A randomized, double-blind, placebocontrolled<br />
trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole<br />
0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005; 53: 791-7.<br />
102. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15%<br />
plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in<br />
mild-to-moderate papulopustular rosacea. J Drugs Dermatol 2010; 9: 607-13.<br />
103. Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale<br />
for combination therapy. J Drugs Dermatol 2012; 11: 838-44.<br />
104. Nybaek H, Jemec GB. Photodynamic therapy in the treatment of rosacea.<br />
Dermatology. 2005; 211: 135-8.<br />
Seite 27 von 29
Change language